期刊文献+

阿托伐他汀钙联合缬沙坦治疗早期糖尿病肾病临床观察 被引量:9

Effects of valsartan combined with atorvastatin in the treatment of early diabetic nephropathy
下载PDF
导出
摘要 目的观察缬沙坦联合阿托伐他汀钙对早期糖尿病肾病患者的治疗作用。方法将确诊为早期糖尿病肾病的62例患者随机分为缬沙坦组、联合治疗组。联合治疗组应用缬沙坦和阿托伐他汀钙治疗;缬沙坦组用缬沙坦治疗,均连续治疗12周,比较两组治疗前后及两组治疗后尿微量白蛋白量、胱抑素、C-反应蛋白、血清总胆固醇、低密度脂蛋白胆固醇等指标的变化。结果将两组治疗前后及联合治疗组与缬沙坦组治疗后分别比较显示,差异有统计学意义(P<0.05)。结论缬沙坦联合阿托伐他汀钙在治疗糖尿病早期阶段能减少患者尿微量白蛋白排泄量,减轻炎症反应,改善肾功能,两药合用起到了协同作用。 Objective To observe the effects of valsartan combined with atorvastatin in the treatment of early diabetic nephropathy. Methods Sixty-two cases were divided into two groups randomly, the control group were treated with valsartan while, the study group were treated with valsartan combined with atorvastatin; after treating for 12 weeks, the clinical effect of the two groups were observed. Results The two groups before and after treatment, the combined treatment group after treatment compared with the valsartan group, the difference was statistically significant (P 〈 0.05). Conclusion Valsartan joint atorvastatin in the treatment of early diabetic nephropathy can reduce the urine trace albu- min excretion and reduce inflammation, improve renal function, curative effect affirmation, two appears to play a synergy.
机构地区 解放军第
出处 《中国现代医生》 2014年第8期62-64,共3页 China Modern Doctor
关键词 糖尿病肾病 缬沙坦 阿托伐他汀钙 尿微量白蛋白 超敏C反应蛋白 胱抑素 Diabetic nephropathy Valsartan Atorvastatin Urinary micro-albumin Hs-CRP Cystatin C
  • 相关文献

参考文献11

二级参考文献55

  • 1翁建平.糖尿病肾病的诊断与治疗[J].临床内科杂志,2005,22(3):150-153. 被引量:79
  • 2俸家富,罗军,李少林.胱抑素C——肾小球滤过率肌酐替代标记物[J].国外医学(临床生物化学与检验学分册),2005,26(3):168-172. 被引量:112
  • 3董梅,孟祥红,佟爱华,李艳艳,吴纯.血清胱抑素C在评价糖尿病患者早期肾损伤中的价值[J].中国实验诊断学,2006,10(6):642-643. 被引量:32
  • 4SEE S. Angiotensin Ⅱ receptor blockers for the treatment of hypertension[J]. Exper Opin Pharmacother, 2001,2(11) :1795.
  • 5Pugsley MK. The angiotensin-Ⅱ(AT Ⅱ ) receptor blocker olmesartan reduces renal damage in anima 1 models of hypertension and diabetes [J]. Proc West Pharmacol Soc,2005,48:35.
  • 6American Diabet es Association, Diabetic nephropathy [J], Diabetes Care,2002,25 (Suppl1) :85-89.
  • 7American Diabetes Association.Diabetic Nephropathy[J].DiabetesCare,2002,25(suppl 1):S85.
  • 8Le Bricon T,Thervet E,Froissart M,et al.Plasma cystatin C issuperior to 24 h creatinine clearance and plasma creatinine for es-timation of glomerular filtration rate 3 months after kidney trans-plantation[J].Clin Chem,2000,46(8):1206.
  • 9Deinum J,Derkx FHM.Cystatin C for estimation of glomerular filtration rate[J].Lancet,2O0O,356:1624.
  • 10Grubb AO.Cystatin C-properties and use as a diagnostic marker[J].Adv Clin Chem,2000,35:63.

共引文献668

同被引文献73

  • 1魏亚.缬沙坦联合阿托伐他汀治疗早期糖尿病肾病临床对照研究[J].临床研究,2014,22(11):78-78. 被引量:1
  • 2Devaraj S,Dasu MR,Jialal I.Diabetes is a proinflammatory state: a translational perspective[J].Expert Rev Endocrinol Metab,2010,5(l):19-28. PMID: 20204165.
  • 3Gensini GF,Gori AM,Dilaghi B,et al.Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study[J].Int J Cardiol,2010,142(3):257-6d. DOI: 10. 1016/j.ijcard.2008.12.213.
  • 4Igoillo-Esteve M,Marselli L,Cunha DA,et al.Palmitate induces a pro-inflammatory response in human pancreatic islets thai mimics CCL2 expression by beta cells in type 2 diabetes[J].Diahetolog ia,2010,53(7): 1395-1405. DOI: 10.1007/s00125-010-1707-y.
  • 5Boni-Schnetzler M,Thorne J,Parnaud G,et al.Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation[J].J Clin Endocrinol Metab,2008,93(10):4065-4074. DOI: 1 0.1210/jc.2008-0396.
  • 6He L,He M,Lv X,et al.NF-kappaB binding activity and proinflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population[J].Diabetes Res Clin Pract,2010,90(1):73-80. DOI: 10.1016/j.diahres.2010.06.016.
  • 7Abdin AA,Hassanien MA,lbrahim EA,et al.Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy[J].J Diabetes Complicatio ns,2010,24(5):325-333. DOI:10.1016/j.jdiacomp.2009.04.001.
  • 8Sasaki J,Ikeda Y,Kuribayashi T,et at.A 52-week, randomized, openlabel, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levt,ls of low-density lipoprotein cholesterol and glucose intolerance[J].Clin Ther,2008,30(6):1089-1101. DOI: 10. 1016/j.clinthera.2008.05.017.
  • 9Uemura Y,Watarai M,Ishii H,et al.Atorvastatin 10 mg plus ezetimibc 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease[J].J Cardiol,201,59(1):50-56. DOI: 10.1016/j.jjcc.2011.09.001.
  • 10CollinsAJ, Kasiske B, Herzog C, et al. United States renal data system 2006 annual data report abstract[ J]. Am J Kidney Dis, 2011,49 ( 1 ) :6-7.

引证文献9

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部